RBM47 has been demonstrated to promote transforming growth factor-β (TGF-β)-induced EMT by alternative splicing of the exon 20 of TJP1 in lung cancer cells [12], and suppress breast cancer progression through altering splicing of a subset of its target mRNAs, such as dickkopf WNT signaling pathway inhibitor 1 [48]. Here, RBM47 is linked to breast carcinoma.